Clinical Trials
7
Active:6
Completed:1
Trial Phases
2 Phases
Phase 1:6
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (85.7%)Phase 2
1 (14.3%)ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE)
- First Posted Date
- 2016-11-04
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- Iltoo Pharma
- Target Recruit Count
- 100
- Registration Number
- NCT02955615
- Locations
- 🇦🇹
AKH Wien, Wien, Austria
🇧🇬University Multiprofile Hospital for Active Treatment, Plovdiv, Bulgaria
🇧🇬University Multiprofile Hospital, Sofia, Bulgaria
News
IL-2 Inhibitor Pipeline Expands with 20+ Companies Developing 22+ Therapeutic Candidates
DelveInsight's 2025 pipeline report reveals over 20 pharmaceutical companies are actively developing 22+ interleukin-2 inhibitor drugs across various clinical stages.
Low-Dose Interleukin-2 Shows Promise in Slowing Motor Neurone Disease Progression in Landmark MIROCALS Trial
The MIROCALS clinical trial demonstrated that low-dose interleukin-2 (IL2LD) is safe and reduced the risk of death by over 40% in approximately 80% of motor neurone disease patients with lower levels of a specific biomarker.